Although bioreactor scale-up often involves matching key engineering parameters, a biology-first approach should dictate the process.

Company demonstrates commercial-scale production of its Toll-like Receptor 5 (TLR5) agonist for Acute Radiation Syndrome (ARS) and Neutropenia through wholly owned contract development manufacturing ...

SHANGHAI, Jan. 19, 2026 /PRNewswire/ -- Smartee Denti-Technology today released its 2025 annual review, detailing a pivotal year characterized by the worldwide clinical application of its proprietary ...